ClinicalTrials.gg
RecruitingNCT05239364CONCLUDEUpdated Apr 30, 2026

Ablation of Consecutive Atrial Tachycardia

An interventional study of Catheter ablation in Heart Arrhythmia, Heart Diseases and Arrhythmias, Cardiac, sponsored by Evangelical Hospital Düsseldorf. Recruiting at 6 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Evangelical Hospital Düsseldorf · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Dec 2020, registered Jan 2022).
  • Started Dec 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies in Arrhythmias, Cardiac with a site in Germany — 15 open to participants now, 19 under way, none of them phase 3. Arrhythmias, Cardiac · Germany.

Planned enrollment
31st of 48
100 · median 210
Started
2020
with 5 others
No phase
28 of 94
5 open now
Primary completion
2027-06
later than 9 of 18 live
Registered
73rd of 94
by date

Among the 94 studies in Arrhythmias, Cardiac with a site in Germany, this one is the 31st largest by planned enrollment of the 48 interventional ones that give a count, is one of 6 that started in 2020, is one of 28 with no phase, reaches primary completion later than 9 of the 18 other live ones, and was the 73rd registered.

Arrhythmias, Cardiac

1,052 studies on the registry are indexed under Arrhythmias, Cardiac; 236 are open to participants now.

Browse Arrhythmias, Cardiac studies →

Open to participants now

15 of the 94 studies in Arrhythmias, Cardiac with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 167 Arrhythmias, Cardiac studies recruiting now, 119 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Arrhythmias, Cardiac with a site in Germany, or all of them as a file.
02

Study summary

Ablation of consecutive atrial tachycardia (AT) after ablation of atrial fibrillation (AF) or cardiac surgery can be challenging due to complex substrate and AT mechanisms. A substantial portion of patients is known to show various tachycardias and recurrences occur in a noticeable number of cases. With the availability of novel ultra-high-density mapping techniques characterization and understanding of AT mechanisms and underlying substrate can be improved. Aim of this prospective, multi-center, randomized study is to compare a standard AT ablation approach versus minimalized ablation of the clinical AT in regards to arrhythmia free survival.

03

Conditions studied

  • Heart Arrhythmia
  • Heart Diseases
  • Arrhythmias, Cardiac
  • Atrial Tachycardia

Keywords

  • Atrial fibrillation
  • Atrial tachycardia
  • Pulmonary vein isolation
  • Electroanatomical mapping
  • High density mapping
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consecutive AT subsequent to prior AF ablation procedure or cardiac surgery
  • Surface -documentation of AT as primary clinical arrhythmia
  • ECG indicating stable, map-able AT (stable activation sequence, and CL stability) with cycle length ≥ 200ms

Exclusion criteria

Exclusion Criteria:

  • \< 18 years
  • No previous atrial fibrillation ablation procedure or cardiac surgery
  • Pregnant women or women of without a negative pregnancy test within 48 hours prior to treatment
  • History of hemorrhagic diathesis or other coagulopathies
  • for oral anticoagulation
  • Hyper- or hypothyroidism
  • Has any condition that would make participation not be in the best interest of the subject
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Standard approach

    Patients will receive a standard approach for ablation of atrial tachycardia.

    Procedure: Catheter ablation

  • Experimental
    Minimalized approach

    Patients will receive a minimalized approach for ablation of atrial tachycardia.

    Procedure: Catheter ablation

Interventions

  • ProcedureCatheter ablation

    Catheter-based ablation of arrhythmias using radiofrequency.

06

What researchers measure

Primary outcomes

  1. Recurrence of any sustained arrhythmia (>30 sec.)

    Time frame: 1 year

Secondary outcomes

  1. Inducibility of atrial tachycardia (AT) after ablation of clinical/primary AT (partial success)

    Categorical variable (yes/no)

    Time frame: Intraprocedural

  2. Predictability of secondary AT by analysis of clinical AT map and voltage map

    Time frame: Intraprocedural

  3. Procedure duration time

    Time frame: Intraprocedural

  4. Fluoroscopy time

    Time frame: intraprocedural

  5. Total radiofrequency application time

    Time frame: intraprocedural

  6. Ablated area (cm2)

    Time frame: intraprocedural

  7. Number of blocked lines

    Time frame: intraprocedural

  8. Area of low voltage in sinus map (cm2)

    Time frame: Intraprocedural

07

Study locations

6 of 6 sites recruiting
  • Asklepios St. Georg
    Hamburg, Free and Hanseatic City of Hamburg, Germany
    Recruiting
    • Stephan Willems, MD · Contact
  • Evangelic Hospital Düsseldorf
    Düsseldorf, North Rhine-Westfalia 40217, Germany
    Recruiting
    • Christian Meyer, MD · Contactchristian.meyer@evk-duesseldorf.de · 00492119191855
    • Katharina Scherschel, PhD · Contactkatharina.scherschel@evk-duesseldorf.de
    • Christian Meyer, MD · Principal investigator
    • Ernan Zhu, MD · Sub investigator
    • Fares A Alken, MD · Sub investigator
    • Bahram Wafaisade, MD · Sub investigator
    • Kristin Risse, MD · Sub investigator
    • Ioana Reismann, MD · Sub investigator
    • Lars Kutsch, MD · Sub investigator
    • Ann-Kathrin Kahle, MD · Sub investigator
  • Vivantes Klinikum Am Urban Berlin
    Berlin, Germany
    Recruiting
    • Niels C Ewertsen, MD · Contact
  • Evangelic Hospital Hagen-Haspe
    Hagen, Germany
    Recruiting
    • Harilaos Bogossian, MD · Contact
  • Städtisches Klinikum Karlsruhe
    Karlsruhe, Germany
    Recruiting
    • Armin Luik, MD · Contact
  • Universitätsklinikum Schleswig Holstein
    Kiel, Germany
    Recruiting
    • Evgeny Lyan, MD · Contact
08

References and documents

Publications

  • Meyer C, Kahle AK, Dagres N, Derval N, Dewland TA, Drago F, Eckardt L, Frontera A, Gerstenfeld EP, Hardy C, Jais P, Kalman J, Kistler PM, Martin C, Purerfellner H, Takigawa M, Wong T, Zeppenfeld K. Management of patients with atrial tachycardia: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), and the Association for European Paediatric and Congenital Cardiology (AEPC). Europace. 2025 Dec 1;27(12):euaf324. doi: 10.1093/europace/euaf324. PubMed 41435855 ↗
  • Jungen C, Akbulak R, Kahle AK, Eickholt C, Schaeffer B, Scherschel K, Dinshaw L, Muenkler P, Schleberger R, Nies M, Gunawardene MA, Klatt N, Hartmann J, Merbold L, Jularic M, Willems S, Meyer C. Outcome after tailored catheter ablation of atrial tachycardia using ultra-high-density mapping. J Cardiovasc Electrophysiol. 2020 Oct;31(10):2645-2652. doi: 10.1111/jce.14703. Epub 2020 Aug 11. PubMed 32748442 ↗
  • Derval N, Takigawa M, Frontera A, Mahida S, Konstantinos V, Denis A, Duchateau J, Pillois X, Yamashita S, Berte B, Thompson N, Hooks D, Pambrun T, Sacher F, Hocini M, Bordachar P, Jais P, Haissaguerre M. Characterization of Complex Atrial Tachycardia in Patients With Previous Atrial Interventions Using High-Resolution Mapping. JACC Clin Electrophysiol. 2020 Jul;6(7):815-826. doi: 10.1016/j.jacep.2020.03.004. Epub 2020 May 27. PubMed 32703564 ↗
  • Meyer C. High-density mapping-based ablation strategies of cardiac rhythm disorders: the RHYTHMIA experience at new horizons. Europace. 2019 Aug 1;21(Supplement_3):iii7-iii10. doi: 10.1093/europace/euz154. No abstract available. PubMed 31400216 ↗
  • Takigawa M, Martin CA, Derval N, Denis A, Vlachos K, Kitamura T, Frontera A, Martin R, Cheniti G, Lam A, Bourier F, Thompson N, Wolf M, Massoulie G, Escande W, Andre C, Zeng LJ, Nakatani Y, Roux JR, Duchateau J, Pambrun T, Sacher F, Cochet H, Hocini M, Haissaguerre M, Jais P. Insights from atrial surface activation throughout atrial tachycardia cycle length: A new mapping tool. Heart Rhythm. 2019 Nov;16(11):1652-1660. doi: 10.1016/j.hrthm.2019.04.029. Epub 2019 Apr 18. PubMed 31004777 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Jun 2027, 78 months after the start.

Of 172 non-industry interventional studies with no phase under Arrhythmias, Cardiac, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 43. This study's planned 78 months is above that.

Counting every sponsor, half of 243 studies reached it within 24 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2022
First posted
Feb 14, 2022
StartActual
Dec 22, 2020
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05239364
Lead sponsor
Evangelical Hospital Düsseldorf
Responsible party
Christian Meyer (Prof. Dr. Christian Meyer, Evangelical Hospital Düsseldorf) — Principal investigator
First posted
Feb 14, 2022
Start date
Dec 22, 2020
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 30, 2026

Study contacts

Christian Meyer, MD
Contact
christian.meyer@evk-duesseldorf.de
00492119191855
Christian Meyer, MD
principal investigator · Evangelic Hospital Düsseldorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion